Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01965730 · ClinicalTrials.gov registry record · Early Phase 1
Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT01965730: Clinical Trial Early Phase 1 study, sponsored by University of Pennsylvania.
NCT01965730 is a Early Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01965730, a Early Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study hopes to determine the optimal antifibrinolytic dosing to decrease bleeding and blood transfusion after cardiac surgery without increasing adverse events
Interventions
- DRUG epsilon-aminocaproic acid (EACA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01965730
The ClinicalTrials.gov registry entry for NCT01965730 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which epsilon-aminocaproic acid (EACA) is the first listed.
NCT01965730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01965730 about?
NCT01965730 is a clinical study titled "Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery". This study hopes to determine the optimal antifibrinolytic dosing to decrease bleeding and blood transfusion after cardiac surgery without increasing adverse events
What is the current status of trial NCT01965730?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2013-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT01965730?
The interventions under investigation include: epsilon-aminocaproic acid (EACA) (DRUG).
Who is sponsoring clinical trial NCT01965730?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.